Safimaltib, a selective allosteric MALT1 protease inhibitor, shows potent antitumor activity in preclinical and clinical studies of B-cell non-Hodgkin lymphomas. See related article by Philippar et al., p. XX See related article by Hertzberg et al., p. XX.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: